ABBV — AbbVie Inc.
Is ABBV overbought or oversold? Here is the current MarketMoodz read.
AbbVie Inc. (ABBV) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Pharmaceuticals) last closed at $292.82. The rating moved from Neutral to Overbought on November 13, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$292.82
- Last changeMoved from Neutral to Overbought on November 13, 2026
- SectorHealthcare
- IndustryPharmaceuticals
See all overbought Healthcare stocks →
AI analysis
AbbVie Inc. (ABBV) combines robust cash generation and a diversified specialty product mix that supports steady shareholder returns and tactical upside from label expansions and pipeline progress. Defensive market flows and the company’s scale mitigate near-term volatility, while significant biosimilar competition to legacy Humira and evolving payer/regulatory dynamics present the primary headwinds. Financial flexibility and a clear portfolio of growth assets provide multiple catalysts; downside scenarios center on faster-than-expected share loss, regulatory reimbursement shifts, or adverse clinical outcomes.
Key factors
- Diversified large-cap pharma franchise with multiple growth drivers (Skyrizi, Rinvoq, other specialty products) reducing reliance on a single product
- Strong free cash flow and balance sheet capacity to support dividends, share buybacks, and targeted M&A
- Defensive sector flows favoring large-cap pharma in risk-averse environments, which can provide relative share support
- Ongoing pipeline and label expansion opportunities that can sustain revenue growth and offset legacy biosimilar pressure
- Operational scale and commercial reach across immunology, oncology, aesthetics and other specialties
Risks
- Continued and accelerated Humira biosimilar erosion could materially reduce legacy revenue beyond current expectations
- Regulatory and payer pressure (including Medicare Advantage integrity measures) that may compress net pricing and increase compliance costs
- Clinical or regulatory setbacks for key growth assets or slower-than-expected uptake for new indications
- Integration and execution risk from acquisitions or portfolio reshaping, potentially weighing on margins
- Macroeconomic volatility or large-scale market rotation reducing defensive flows into big pharma
Latest MarketMoodz coverage
- Genmab/AbbVie Lymphoma Trial Shows PFS Win; Upside Ahead2026-06-30
- Congressional Probe into Merck, AbbVie China Trials Raises Risk2026-06-30
- AbbVie Scores Dermatology Wins, Buys Apogee for $10.9B2026-06-29
- Nine-Year Venetoclax Data Bolsters AbbVie's CLL Case2026-06-12
- Supreme Court Lets Biden Medicare Drug-Price Rule Stand2026-05-19
See today's live rating, score and targets
Members see the live hourly rating for ABBV — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.